Cargando…
COVID-19 vaccination and diabetic ketoacidosis
An efficient coronavirus disease 2019 (COVID-19) vaccine is urgently required to fight the pandemic due to its high transmission rate and quick dissemination. There have been numerous reports on the side effects of the COVID-19 immu-nization, with a focus on its negative effects. Clinical endocrinol...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236999/ https://www.ncbi.nlm.nih.gov/pubmed/37273244 http://dx.doi.org/10.4239/wjd.v14.i5.560 |
_version_ | 1785053065738452992 |
---|---|
author | Joob, Beuy Wiwanitkit, Viroj |
author_facet | Joob, Beuy Wiwanitkit, Viroj |
author_sort | Joob, Beuy |
collection | PubMed |
description | An efficient coronavirus disease 2019 (COVID-19) vaccine is urgently required to fight the pandemic due to its high transmission rate and quick dissemination. There have been numerous reports on the side effects of the COVID-19 immu-nization, with a focus on its negative effects. Clinical endocrinology is extremely interested in the endocrine issue that arises after receiving the COVID-19 vaccine. As was already mentioned, after receiving the COVID-19 vaccine, many clinical problems could occur. Additionally, there are some compelling reports on diabetes. After receiving the COVID-19 vaccine, a patient experienced hyperosmolar hyperglycemia state, a case of newly-onset type 2 diabetes. There has also been information on a potential connection between the COVID-19 vaccine and diabetic ketoacidosis. Common symptoms include thirst, polydipsia, polyuria, palpitations, a lack of appetite, and weariness. In extremely rare clinical circumstances, a COVID-19 vaccine recipient may develop diabetes complications such as hyperglycemia and ketoacidosis. In these circumstances, routine clinical care has a successful track record. It is advised to give vaccine recipients who are vulnerable to problems, such as those with type 1 diabetes as an underlying illness, extra attention. |
format | Online Article Text |
id | pubmed-10236999 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-102369992023-06-03 COVID-19 vaccination and diabetic ketoacidosis Joob, Beuy Wiwanitkit, Viroj World J Diabetes Minireviews An efficient coronavirus disease 2019 (COVID-19) vaccine is urgently required to fight the pandemic due to its high transmission rate and quick dissemination. There have been numerous reports on the side effects of the COVID-19 immu-nization, with a focus on its negative effects. Clinical endocrinology is extremely interested in the endocrine issue that arises after receiving the COVID-19 vaccine. As was already mentioned, after receiving the COVID-19 vaccine, many clinical problems could occur. Additionally, there are some compelling reports on diabetes. After receiving the COVID-19 vaccine, a patient experienced hyperosmolar hyperglycemia state, a case of newly-onset type 2 diabetes. There has also been information on a potential connection between the COVID-19 vaccine and diabetic ketoacidosis. Common symptoms include thirst, polydipsia, polyuria, palpitations, a lack of appetite, and weariness. In extremely rare clinical circumstances, a COVID-19 vaccine recipient may develop diabetes complications such as hyperglycemia and ketoacidosis. In these circumstances, routine clinical care has a successful track record. It is advised to give vaccine recipients who are vulnerable to problems, such as those with type 1 diabetes as an underlying illness, extra attention. Baishideng Publishing Group Inc 2023-05-15 2023-05-15 /pmc/articles/PMC10236999/ /pubmed/37273244 http://dx.doi.org/10.4239/wjd.v14.i5.560 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Minireviews Joob, Beuy Wiwanitkit, Viroj COVID-19 vaccination and diabetic ketoacidosis |
title | COVID-19 vaccination and diabetic ketoacidosis |
title_full | COVID-19 vaccination and diabetic ketoacidosis |
title_fullStr | COVID-19 vaccination and diabetic ketoacidosis |
title_full_unstemmed | COVID-19 vaccination and diabetic ketoacidosis |
title_short | COVID-19 vaccination and diabetic ketoacidosis |
title_sort | covid-19 vaccination and diabetic ketoacidosis |
topic | Minireviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236999/ https://www.ncbi.nlm.nih.gov/pubmed/37273244 http://dx.doi.org/10.4239/wjd.v14.i5.560 |
work_keys_str_mv | AT joobbeuy covid19vaccinationanddiabeticketoacidosis AT wiwanitkitviroj covid19vaccinationanddiabeticketoacidosis |